Sequential chemotherapy regimen of induction with panitumumab and paclitaxel followed by radiotherapy and panitumumab in patients with locally advanced head and neck cancer unfit for platinum derivatives. The phase II, PANTERA/TTCC-2010-06 study.
Javier Martínez TruferoA Lozano BorbalasI Pajares BernadM Taberna SanzE Ortega IzquierdoB Cirauqui CirauquiJ Rubió-CasadevallM Plana SerrahimaJ M Ponce OrtegaI Planas ToledanoJ CaballeroJ Marruecos QuerolL Iglesias DocampoJ Lambea SorrosalJ C AdansaR Mesía Ninnull nullPublished in: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico (2021)
Although underpowered, ORR was higher than the pre-specified boundary for considering the treatment active. Although Px + Pb as IT provides some benefit, the safety profile is worse than expected. To consider Pb + Px as IT as an alternative for platinum-unsuitable LA-SCCHN, further research/investigation would be needed.
Keyphrases
- locally advanced
- phase ii
- rectal cancer
- neoadjuvant chemotherapy
- squamous cell carcinoma
- clinical trial
- heavy metals
- radiation therapy
- phase ii study
- open label
- metastatic colorectal cancer
- wild type
- early stage
- risk assessment
- radiation induced
- double blind
- lymph node
- placebo controlled
- chemotherapy induced
- smoking cessation